ArticleFEMS immunology and medical microbiology2009
Identification and characterization of novel recombinant vaccine antigens for immunization against genital Chlamydia trachomatis.
Article in FEMS immunology and medical microbiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 42 citations in OpenAlex.
- Interferon-γ Responses to Chlamydia trachomatis Vaccine Candidate Proteins in Women With Different Chlamydia Outcomes.The Journal of infectious diseases · 2024Article
- Article
- A primary Chlamydia trachomatis genital infection of rhesus macaques identifies new immunodominant B-cell antigens.PloS one · 2021Article
- Induction of protection in mice against a respiratory challenge by a vaccine formulated with exosomes isolated fromNPJ vaccines · 2020Article
- Parenteral vaccination protects against transcervical infection withNPJ vaccines · 2020Article
- Genital Infiltrations of CD4Frontiers in microbiology · 2019Article
- Chlamydial protease-like activity factor mediated protection against C. trachomatis in guinea pigs.Immunology and cell biology · 2017Article
- Update on Chlamydia trachomatis Vaccinology.Clinical and vaccine immunology : CVI · 2017Review
- Profiling and validation of individual and patterns of Chlamydia trachomatis-specific antibody responses in trachomatous trichiasis.Parasites & vectors · 2017Article
- A Protective Vaccine against Chlamydia Genital Infection Using Vault Nanoparticles without an Added Adjuvant.Vaccines · 2017Article
- Article
- Article
- A multi-subunit Chlamydia vaccine inducing neutralizing antibodies and strong IFN-γ⁺ CMI responses protects against a genital infection in minipigs.Immunology and cell biology · 2016Article
- Chlamydial polymorphic membrane proteins: regulation, function and potential vaccine candidates.Virulence · 2016Review
- Resolution of Chlamydia trachomatis Infection Is Associated with a Distinct T Cell Response Profile.Clinical and vaccine immunology : CVI · 2015Article
- Article
- Frequency of Chlamydia trachomatis-specific T cell interferon-γ and interleukin-17 responses in CD4-enriched peripheral blood mononuclear cells of sexually active adolescent females.Journal of reproductive immunology · 2014Article
- Immunity, immunopathology, and human vaccine development against sexually transmitted Chlamydia trachomatis.Human vaccines & immunotherapeutics · 2014Review
- Formulation, characterization, and expression of a recombinant MOMP Chlamydia trachomatis DNA vaccine encapsulated in chitosan nanoparticles.International journal of nanomedicine · 2013Article
- Proteomic identification of immunodominant chlamydial antigens in a mouse model.Journal of proteomics · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 3 countries.
Funding
Abstract
Chlamydia trachomatis infection is the most common sexually transmitted bacterial infection worldwide, with over 91 million cases estimated annually. An effective subunit vaccine against Chlamydia may require a multivalent subunit cocktail of antigens in a single formulation for broad coverage of a heterogeneous major histocompatibility complex population. Herein, we describe the identification of novel C. trachomatis antigens by CD4+ and CD8+ T-cell expression cloning, serological expression cloning, and an in silico analysis of the C. trachomatis genome. These antigens elicited human CD4+ T-cell responses, and a subset proved to be immunogenic and protective when administered as immunoprophylactic vaccines against C. trachomatis challenge. Candidate vaccines consisting of the prioritized C. trachomatis antigens adjuvanted in a GlaxoSmithKline proprietary AS01B adjuvant were prioritized based on induction of solid protection against challenge in C57BL/6 and BALB/c mice with C. trachomatis. Some of the vaccines prevented bacterial shedding and colonization of the upper genital tract to varying degrees by mechanisms that may include CD4+ T cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.